OTCPicks.com

FEATURED COMPANY

CELEBDIRECT INCORPORATED (OTC: CELI)

Detailed Quote: http://www.otcpicks.com/quotes/CELI.php

Company Profile: http://www.otcpicks.com/celebdirect/celebdirect-2.htm

CelebDirect's primary business is that of a direct response celebrity incubator and has two divisions which are direct response marketing and Celebrity placement / franchise opportunities. CelebDirect brings to the market unique and innovative products via direct to market strategies such as infomercials, advertorials and other associated advertising vehicles to expeditiously, economically and broadly market products throughout North American as well as a global basis. CelebDirect has a number of consumer-oriented products it is evaluating and others it is currently bringing to market.

CELI News:

July 17 - CelebDirect Provides a Corporate Update to Investors

CelebDirect (OTC: CELI) recently provided a corporate update to investors regarding the company.

Complete corporate information can be found at:

http://www.pinksheets.com/pink/quote/quote.jsp?symbol=celi.

Financial

CelebDirect is in the process of completing its 2007 audit as part of its ongoing financial and material change disclosure policy. Corso & Company have been retained as the company’s Auditor. As well, Q1 and Q2 2008 financial results will be made available upon their completion at which time CelebDirect shall follow a pattern of timely quarterly disclosure practices.

CelebDirect has no debt and has a very low fixed cost structure. CelebDirect’s entire supply chain from Order Capture to Product Logistics is established on third party relationships through scaled volume contracts. Danny Alex, CEO of CelebDirect, takes a salary of $1.00 per year. The current fixed cost structure of the company on a monthly basis is below $7,000.00 since Danny Alex assumed the role of CEO back in early March.

The philosophy of CelebDirect is; “Dilution” erodes shareholder value while “Retained Earnings” builds shareholder value. It is this principle by which management operates and makes decisions on behalf of all shareholders.

Board of Directors

Robert Phan, Juan Garcia, Eddie Dang and Gregg Phan have resigned from the Board of Directors of CelebDirect. Two new Directors have been added to the Board, Thomas Jones and Sid Dutchak:

Sid Dutchak

Mr. Dutchak has served on several public company Boards, and within the past five years served on the Boards of How To Web TV Inc., Ergo Ventures Inc. and Maple Leaf Reforestation Inc, all of which are public companies. Mr. Dutchak served as the Province of Saskatchewan’s Minister of Justice. He previously practiced law and has served on various public companies as a director, officer and senior manager.

Thomas Jones

Tom Jones is the inventor of the Muscle Flex and has well over 30 years of experience in Martial Arts. He has a 4th degree black belt in Karate and holds national, international, and world kick boxing titles. Tom also holds 2 world records in the sport of running. Tom Jones is an extreme athlete, motivational speaker, martial arts expert, international kickboxing champion, endurance runner, inventor, humanitarian and child advocate.

OTCBB / 15c 211

CelebDirect is preparing its application for listing to the OTC Bulletin Board. The law firm of Applbaum / Zouvas has been retained to complete its 15c 211 and take the appropriate steps in the hopes to qualify for listing on the OTC Bulletin Board.

FEATURED COMPANY

XSUNX INCORPORATED (OTCBB: XSNX)

Detailed Quote: http://www.otcpicks.com/quotes/XSNX.php

Company Profile: http://www.otcpicks.com/xsunx/xsunx.htm

Xsunx, Inc., a thin-film photovoltaic (TFPV) company, focuses on developing thin film photovoltaic (TFPV) amorphous silicon solar cell manufacturing processes to produce TFPV solar modules. Its product includes XsunX ASI-120 module, which is a 125 peak watt TFPV solar module utilizing glass substrates and a proprietary semiconductor manufacturing system. XsunX ASI-120 provides for a module delivering high power output, and size and framing that would allow for the use of various existing mounting systems. The target markets for the TFPV solar module include solar farms, government agencies, and utility companies, as well as power purchase agreements and large commercial installations worldwide. The company, formerly known as Sun River Mining, Inc., was incorporated in 1997 and changed its name to XsunX, Inc. in 2003. XsunX is headquartered in Aliso Viejo, California.

XSNX News:

July 16 - XsunX Expands Efforts to Secure Oregon Financial Incentives and Supply Statewide Burgeoning Renewable Energy Initiatives

XsunX, Inc. (OTCBB: XSNX), a solar technology Company engaged in the build- out of its multi-megawatt thin film photovoltaic (TFPV) solar manufacturing facilities, announced that efforts in the state of Oregon to establish its manufacturing facilities, qualify for state sponsored investment tax credits, low interest financing opportunities, and work towards establishing a presence as a qualified supplier to the states burgeoning renewable energy initiatives is gaining momentum.

The Company took possession of its leased TFPV manufacturing facilities two weeks ahead of schedule. With its corporate presence now firmly established in Oregon XsunX also recently submitted its first petition seeking certification for Oregon State Business Energy Tax Credits (BETC). With the BETC application XsunX is seeking up to approximately $20 million in tax credits for investments made by the Company in its TFPV solar module manufacturing systems. The state has established a program whereby BETC tax credits, if secured, can be marketed or resold at slightly more than half their face value to qualified companies in Oregon. The application for the BETC program also serves as a pre-certification in the Company's efforts to secure long term low interest loans from the state of Oregon for use in the build out and expansion of the first and subsequent phases of its planned 100MW of TFPV manufacturing infrastructure.

"Finalizing our lease and the presence of our new TFPV manufacturing facilities provides us with a milestone we've been planning for since last fall," stated Tom Djokovich, XsunX's CEO. "This milestone allows us to now work towards securing a number of the great incentives offered by Oregon and its progressive efforts to attract and establish a strong renewable industry. We've now submitted our applications for two of the larger incentive packages potentially worth many millions to us, and we've also begun bidding to supply a significant amount of renewable energy projects around the state. While the confidence in many of the financial aspects of the U.S. economy may be in flux one thing we're confident in at XsunX is that the need for alternate and diverse sources of energy is at an all time high. We are continuing to stay focused on the big picture and the long term value we see in the solar sector, and XsunX, is working to reduce dependence on carbon based fuels," concluded Djokovich.

FEATURED COMPANY

MONOGRAM ENERGY INCORPORATED (OTC: MGRN)

Detailed Quote: www.otcpicks.com/quotes/MGRN.php

Company Profile:
www.otcpicks.com/monogram-energy/monogram-energy.htm

Monogram Energy, Inc. is an independent energy company engaged in the acquisition, development, and exploitation of oil and gas properties. The company specializes in acquiring oil & gas leases with proven reserves that have the potential for increased production.

MGRN News:

July 16 - Monogram Energy, Inc. Reaches Agreement on New Lease

Monogram Energy, Inc. (OTC: MGRN) announced it has reached an agreement in principle to acquire 25% interest in a re-work well in the Williston basin located in Montana. As reported earlier, it is believed that this well has the capability to produce from 600 to 2,000 barrels of oil per day. Further, Monogram Energy, Inc. is excited because this agreement solidifies a relationship that opens the door to 180 acres of prospects located in the Williston basin. The Williston basin represents the largest North American oil find in history.

Mr. Billy King, Chief Executive Officer of Monogram Energy, Inc., stated, "We think this well has tremendous potential and could double the profit margin of the Company."

Mr. King became interested in the production of oil & gas during his ten years of employment as an attorney for the Halliburton Company, and with his representation of independent oil companies during his years as a private practitioner. Monogram Energy's goal is to maintain a high risk/reward profile, thereby enabling them to return the most value to its shareholders.

FEATURED COMPANY

COPPER KING MINING CORPORATION (OTC: CPRK)

Detailed Quote: www.otcpicks.com/quotes/CPRK.php

Company Profile:
www.otcpicks.com/copper-king-mining/copper-king-mining.htm

Copper King Mining Corporation currently owns approximately 1200 acres in the Drum Mountains of Utah, which are patent deeded mining claims which contain gold, silver and copper. The company recently added to its holdings by filing six more claims on land which was inside their holdings, but not patent deeded. Contiguous to that acreage is approximately 1100 acres of claims filed by Western Utah Copper Company. As the companies explored the concept of a joint venture on the Drum Mountain properties, it was decided that a very viable consideration was to join the total assets of both companies.

CPRK News:

July 15 - Copper King Mining Corporation Announces Construction Updates

Copper King Mining Corporation (OTC: CPRK), an ore mining, processing, and Exploration company located in Southern Utah, today offered updates regarding its Floatation Mill’s construction near Milford, Utah.

Copper King announced today that it awarded the bid to construct the substation that will supply power to the Copper King concentrator as part of its Floatation Mill construction to AF Electric. AF intends to begin work next week. Construction of the Master Control Center building has commenced and is targeted to be completed in 3 weeks. Placement of electric cable trays and heavy conduit inside the concentrator, which will provide power to the ball mills and cyclone deck, will begin this week also.

July 15 - Copper King Mining Corporation Offers Corporate Updates

Copper King Mining Corporation (OTC: CPRK), an ore mining, processing, and exploration company located in Southern Utah, provided updates concerning prior officers of Copper King Mining Corporation.

In response to shareholder inquiry, Copper King announced that neither Daryl nor Sandra Nether are Copper King officers, directors or insiders and are not involved in the company’s operations. Daryl and Sandra Nethers are Copper King shareholders. The company is in the process of updating its information on Pink Sheets.com in order to remove any incorrect, outdated, inaccurate or derogatory data. Pink Sheets.com is not a governmental regulatory entity but rather a private company that provides a forum to lodge information about companies listed on the Pink Sheet Exchange to the public.

FEATURED COMPANY

WIND ENERGY AMERICA INCORPORATED (OTCBB: WNEA)

Detailed Quote: www.otcpicks.com/quotes/WNEA.php

Company Profile:
www.otcpicks.com/wind-energy-america/wind-energy-america-2.htm

Wind Energy America Inc. develops and operates wind energy projects in the Great Plains and the Midwest, regions known for their high quality wind energy resources. The Company owns interests in three wind farms: Shaokatan Hills LLC, Lakota Ridge LLC and CHI Energy. At present, WNEA owns a developer's stake and a minimal interest producing negligible cash flow in these wind farms. Over the next two years the developer’s stake will begin producing significant cash flow from these projects. The three wind farms together contain 79 modern wind turbines and have a total rated capacity of 53.5 megawatts (MW). They are collectively generating approximately 160 million kilowatt hours (kWh) of electricity annually. In addition to these properties, the Company owns a 3 percent equity interest in Averill Wind LLC, a 10 MW wind farm being developed near Fargo, N.D., another region favorable for wind power energy.

WNEA News:

July 15 - Wind Energy America Inc. Rated 'Buy' by BrokerBank Securities

Wind Energy America Inc. (OTCBB: WNEA) has been rated a “Buy” by BrokerBank Securities’ Philip Wright, CFA.

The full report is available via download at https://brokerbanksecurities.com.

In the report, the analyst writes, “Boreal assets purchased by the Company included Boreal’s interests and development rights to various wind farm projects in the Upper Midwest and Great Plains regions and located in some of the most favorable wind regimes in North America for generation of electricity from wind power turbines. This extensive “pipeline” of wind power projects includes approximately 1,200 megawatts of rated turbine power capacity in various phases of design or development. WNEA shares are a BUY. These shares could triple in 12 months.”

FEATURED COMPANY

LANTIS LASER INCORPORATED (OTC: LLSR)

Detailed Quote: http://www.otcpicks.com/quotes/LLSR.php

Company Profile: http://www.otcpicks.com/lantis-laser/lantis-laser-2.htm

Lantis Laser was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System™ in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); LightLab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser, visit www.lantislaser.com.

LLSR News:

July 15 - Lantis' OCT Dental Imaging System Featured in Report on Light-Based Diagnostic Modalities for Early Decay

Lantis Laser Inc. (OTC: LLSR) (www.lantislaser.com) issued a statement drawing attention to a recent significant report on a leading professional dental website, www.DrBicuspid.com, highlighting the status of light-based diagnostic modalities for the early detection of decay.

Early detection of decay is an important part in the practice of minimally invasive dentistry and the “medical model” of finding disease early and treating it early with topical or chemical means to avoid surgical intervention.

Lantis' OCT Dental System is addressed in Part III.

The report was published on the Internet in three parts, with the last, Part III, titled:

"Beyond x-rays: Part III — OCT brings early decay to light" www.drbicuspid.com/index.aspx?sec=sup&sub=img&pag=dis&ItemID=300735&wf=34

Links to Part I and Part II, which discuss currently available diagnostic products, are accessible at the end of Part III.

Lantis' OCT Dental Imaging System is based on novel, light-based bio-medical imaging technology, Optical Coherence Tomography (OCT), that enables the dentist to do diagnostic imaging, chairside and in real-time. Images can be captured at a resolution of up to 10 times that of x-ray, enabling early detection of decay and detailed examination of microstructural defects. As the power source is light-based, unlike x-ray there is no harmful radiation.

STOCKS TO WATCH

EXIT ONLY INCORPORATED (OTC: EXTO)
"Up 89.47% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/EXTO.php

Exit-Only, Inc. operates as an Internet-based market for new and used vehicles in Canada. The company operates Text4Cars.Com Web site that contains a database of new and used vehicles, where sellers can add to the site and buyers can search and purchase from the site. As of May 22, 2007, Text4Cars.Com had approximately 10,000 vehicles on its database. The company was incorporated in 2006 and is based in Santa Monica, California.

EXTO News:

July 17 - Text-4-Cars.com Signs L.O.I. for Joint Venture With Optical Systems, Inc.

Partnership Opens New Locations and Additional Revenue

Text-4-Cars.com, a wholly owned subsidiary of Exit Only, Inc. (OTC: EXTO), announced that it has signed a L.O.I. to enter into a joint venture with Optical Systems, Inc. With the current projections, this partnership should increase Text-4-Cars revenues by as much as 30 percent. Through this partnership, Text-4-Cars.com will offer their SMS services throughout the Save-A-Deal Auto Network while additionally implementing a new lead program that produces a significant new revenue stream to their business model.

"We are very excited about our new venture with Optical Systems, Inc. Our premium service along with their back-end office solutions will enhance any dealerships' revenues as well as provide new sales opportunities. We will be releasing more information in the near future as to the significant impact this will have on our revenues in the near future," stated Kyle Gottschalk, C.E.O. and President of Exit Only, Inc.

TEXT4CARS.COM provides no cost advertising to sellers of vehicles. When a qualified buyer expresses interest, contact information is instantaneously delivered to the seller who is then charged a token fee. Buyers, sellers, dealers and private parties have agreed that TEXT4CARS.COM is the most efficient, low cost and prompt way to buy or sell a car.

For more information, visit www.text4cars.com or www.goldenboards.com.

CATALYST SEMICONDUCTOR INCORPORATED (NASDAQ: CATS)
"Up 52.96% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CATS.php

Catalyst Semiconductor, Inc. engages in the design, development, and marketing of reprogrammable non-volatile memory products and analog/mixed-signal semiconductor products. The company's products include electrically erasable programmable read-only memory (EEPROM) and flash memory products, which are used in applications to store user reconfigurable data, and in personal computers, cellular handsets, digital cameras, optical networks, wireless local area networks, digital set-top boxes, automotive systems, LCD televisions, digital video recorders, cordless phones, laser printers, memory modules for computers, disk drives, and remote controls; and analog and mixed-signal products comprising supervisory products with EEPROM, supervisory products without memory, digitally programmable potentiometers, white LED drivers, DC to DC converters, LDO regulators, and input/output expanders, which are used in the applications, such as power management, systems supervision, and interface support. Its products are used by manufacturers of electronic products in a range of consumer, computing, communications, industrial, and automotive applications. Catalyst Semiconductor distributes its products through manufacturers' representatives, distributors, and resellers in North America, South America, Europe, Africa, and Asia. The company was founded in 1985 and is headquartered in Santa Clara, California.

CATS News:

July 17 - ON Semiconductor to Acquire Catalyst Semiconductor, Inc. in an All-Stock Transaction

ON Semiconductor Corporation (NASDAQ: ONNN) and Catalyst Semiconductor, Inc. (NASDAQ: CATS) announced the signing of a definitive merger agreement providing for the acquisition of Catalyst Semiconductor by ON Semiconductor in an all-stock transaction in which Catalyst shareholders will receive 0.706 shares of ON Semiconductor common stock for each share of Catalyst common stock they own. This represents an equity value of approximately $115 million and an enterprise value of approximately $85 million.

“The acquisition of Catalyst Semiconductor will add to our high gross margin analog and mixed-signal product offerings for the digital consumer and wireless end-markets,” said Keith Jackson, ON Semiconductor president and CEO. “Catalyst Semiconductor’s analog and mixed-signal business represented more than $11 million in sales as of their April 2008 fiscal year end - a business that grew more than 90 percent versus the prior year. Catalyst Semiconductor’s EEPROM technology will strengthen our custom application-specific circuits (ASIC) and power products capabilities expanding our ability to more comprehensively address our customers’ needs. With the combination of ON Semiconductor's global footprint, effective channels of distribution, and top-tier customer relationships, we expect to be able to support a broader and deeper penetration of Catalyst's overall product portfolio. This should enable us to accelerate their revenue growth and increase market share. We also believe additional revenue from Catalyst Semiconductor’s strong portfolio offering will benefit from ON Semiconductor’s manufacturing capabilities. We look forward to welcoming Gelu Voicu, Catalyst Semiconductor’s CEO, as well as the talented Catalyst employee base to ON Semiconductor.”

“This transaction represents a compelling opportunity for Catalyst employees, customers and shareholders,” stated Gelu Voicu, CEO of Catalyst Semiconductor. “To compete successfully in today’s global marketplace, size and scale are very important. We are pleased to become part of a leading global company in the semiconductor sector. ON Semiconductor’s world-class operational capabilities and supply chain will enable Catalyst Semiconductor’s products to better penetrate the automotive, consumer, and industrial end-markets utilizing ON Semiconductor’s global customer and channel footprint.“

Transaction Details

Under the terms of the agreement, which has been approved by both boards of directors, the fixed exchange ratio will be 0.706 shares of ON Semiconductor common stock for each share of Catalyst Semiconductor common stock. Based on the closing stock price of ON Semiconductor on July 16, 2008, this represents a value to Catalyst Semiconductor shareholders of approximately $6.24 per share. Upon completion of the transaction, ON Semiconductor will issue approximately 13 million shares of common stock on a fully diluted basis to complete the transaction or approximately 3 percent of ON Semiconductor’s fully diluted shares outstanding.

The transaction is subject to the approval of shareholders of Catalyst Semiconductor as well as customary closing conditions and regulatory approvals. The companies expect the transaction to close in the fourth quarter of 2008. Upon closing, ON Semiconductor may record a one-time charge for purchased in-process research and development expenses and other deal related costs. The amount of that charge, if any, has not yet been determined.

“This acquisition is directly aligned with both our strategic and financial goals,” said Donald Colvin, ON Semiconductor executive vice president and CFO. “Net of cash and short term investments of approximately $30 million at the end of April 2008, the transaction value represents approximately 1.1 times trailing twelve month sales. We also believe ON Semiconductor’s operational strengths will significantly benefit the revenue and margin potential of Catalyst Semiconductor. Excluding the impact of amortization expense, write-up of inventory to fair market value, one-time and other deal related charges discussed above, we expect the acquisition will have minimal impact to earnings per share in the first year post the transaction close and should be accretive to our earnings per share thereafter. ON Semiconductor’s business and the integration of AMIS Holdings, Inc. has proceeded as anticipated and we are comfortable with the guidance and current level of revenue and earnings expectations provided on our May 5, 2008 conference call. We intend to provide further details on the acquisition and our second quarter 2008 results on our regularly scheduled quarterly earnings conference call on Aug. 6, 2008.”

Shares of the combined company will trade on the NASDAQ Global Exchange under the symbol “ONNN.” JP Morgan acted as exclusive financial advisor and DLA Piper US LLP acted as legal counsel to ON Semiconductor. Houlihan Lokey acted as exclusive financial advisor and O’Melveny & Myers LLP acted as legal counsel to Catalyst Semiconductor.

Teleconference and Webcast Information

ON Semiconductor will host a conference call for the financial community at 8:00 a.m. Eastern Time (ET) on Aug. 6, 2008 to discuss this announcement and ON Semiconductor’s results for the second quarter of 2008. The company will also provide a real-time audio broadcast of the teleconference on the Investor Relations page of its website at www.onsemi.com. The webcast replay will be available at this site approximately one hour following the live broadcast and will continue to be available for approximately 30 days following the conference call. Investors and interested parties can also access the conference call through a telephone call by dialing (888) 546-9664 (U.S./Canada) or 706-679-4331 (International). In order to join this conference call, you will be required to provide the Conference ID Number, which is 56464044. Approximately one hour following the live broadcast, the company will provide a dial-in replay that will continue to be available through August 13, 2008. To listen to the teleconference replay, call 800-642-1687 (U.S./Canada) or 706-645-9291 (International). You will be required to provide the Conference ID Number, which is 56464044.

About ON Semiconductor

With its global logistics network and strong product portfolio, ON Semiconductor (NASDAQ: ONNN) is a preferred supplier of high performance energy efficient silicon solutions to customers in the power supply, automotive, communication, computer, consumer, medical, industrial, mobile phone, and military/aerospace markets. The company’s broad portfolio includes power, signal management, analog, DSP, advance logic, clock management and standard component devices. Global corporate headquarters are located in Phoenix, Arizona. The company operates a network of manufacturing facilities, sales offices and design centers in key markets throughout North America, Europe, and the Asia Pacific regions. For more information, visit www.onsemi.com.

BIOVEST INTERNATIONAL INCORPORATED (OTCBB: BVTI)
"Up 36.36% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/BVTI.php

Biovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ: ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently completing a pivotal Phase 3 clinical trial for BiovaxID®, which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.

BVTI News:

July 17 - Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID® Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial

* Overall median disease-free-survival increased by more than one year (p-value = 0.047)
* 100% improvement in disease-free-survival at three years (p-value = 0.024)
* Potential to be first ever anti-cancer vaccine approved in U.S. and/or Europe

Biovest International, Inc. (OTCBB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI), announced clinically and statistically significant unblinded data from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial of BiovaxID® (personalized anti-idiotype vaccine) for the treatment of indolent follicular non-Hodgkin’s lymphoma (NHL), an often fatal blood cancer. Originally developed and advanced into human clinical trials by the National Cancer Institute (NCI), BiovaxID is designed to recruit the immune system to recognize and destroy only cancerous B-cells. Based on this study’s highly encouraging clinical evidence reporting on vaccinated patients to date, including efficacy and safety, Biovest intends to move forward with plans to seek accelerated and/or conditional regulatory approvals in the U.S. and European Union, respectively.

Summary Results

Biovest reported on two clinically relevant data points: 1) Overall median disease-free survival data as measured up to 80 months; and 2) Disease-free survival data on these same patients as measured at three years. All analyses performed were predetermined prior to unblinding and consistent with the Statistical Analysis Plan that was submitted and accepted by the FDA and the data review performed by the independent Data Monitoring Committee (DMC), which is vested with the responsibility for monitoring the safety and efficacy of the BiovaxID trial.

First, for vaccinated patients followed up to 80 months, the overall results showed that BiovaxID improved median disease-free-survival by more than one year with the control arm showing a median time to relapse from first vaccination of 21.2 months, as compared to the BiovaxID arm which had a median time to relapse of 33.8 months. This statistically significant difference (p-value = 0.047) represents an increase of approximately 60% in the duration of complete remission since first vaccination. Disease-free survival (how long patients remain in cancer-free remission) is the primary endpoint of the study.

Second, for these same patients measured at 36 months from vaccination, BiovaxID improved median disease-free-survival by approximately 100% — a statistically significant improvement as compared to the control group (p-value = 0.024).

Biovest intends to seek accelerated and/or conditional approvals immediately in the U.S. and Europe, respectively, based on the current unblinded data and plans to supplement the clinical analysis with additional follow-up data through August 29, 2008, as per the recommendation of the DMC.

According to the Leukemia & Lymphoma Society, non-Hodgkin’s lymphoma is the 5th leading cause of new cancer cases in the U.S., with an estimated 63,190 new cases of NHL to be diagnosed in 2008, with approximately 18,660 deaths expected to be attributed to the disease. In Europe, NHL is the 6th most common form of cancer with approximately 50,000 new cases diagnosed each year in the European Union alone.

ABOUT BIOVAXID®

BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, we anticipate that BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.

ABOUT ACCENTIA BIOPHARMACEUTICALS, INC.

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is committed to building significant value for its stockholders through the commercialization of patent-protected disruptive healthcare technologies designed to be positioned as leading products for the treatment of a broad range of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. The Company generated more than $18 million in revenues in fiscal-year 2007, primarily based on sales of its marketed specialty pharmaceutical products and its analytical consulting business serving biopharmaceutical clients.

Accentia is advancing a portfolio of potential blockbuster drug candidates which target multi-billion dollar market opportunities. These late-stage products include: BiovaxID®, a novel anti-idiotype cancer vaccine for the treatment of B-cell malignancies including indolent follicular non-Hodgkin’s lymphoma; Revimmune™, a novel ultra-high-dose formulation of a previously approved chemotherapeutic agent expected to show utility in the treatment of up to 80 autoimmune diseases, with an initial focus on multiple sclerosis; and SinuNase™, a novel formulation of a previously approved anti-fungal for the topical, intranasal treatment of chronic sinusitis.

Accentia’s interest in BiovaxID is based on its majority ownership stake in Biovest International, Inc. (OTCBB: BVTI). And Accentia also maintains a royalty interest in Biovest’s biologic products. Accentia is a portfolio company of the Hopkins Capital Group.

For further information, visit www.biovest.com.

BROWNSTONE RESOURCES INCORPORATED (OTC: BWNR)
"Up 21.43% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/BWNR.php

Brownstone is a gold exploration company focused on creating value for shareholders by exploring and developing high-grade gold mining properties. Details of Brownstones projects are available on the Company's website at www.brownstoneresources.com.

BWNR News:

July 15 - Brownstone Completes Earn in of 'LS Grande' Gold/Silver/Copper Property, Comments on Approval of 'Phase One' Plan

Brownstone Resources Inc. (OTC: BWNR) announced that the company has completed their option payments to date as required for the earn in portion of the "LS Grande" gold/silver/copper property, located in NE Arizona.

Additionally, Brownstone has received the "Phase One" development plan for the LS Grande, and is in the process of reviewing the plan for approval. Management anticipates final approval of the plan within the next few days.

"We are really excited about the prospects of the LS Grande property, the potential of the project and the effectiveness of the plan to deliver the results we are after. We have completed some limited ground geophysics, and collected surface samples for assaying... now we are going to proceed with putting a few holes down and, in due course, move forward with the completion of phase one," said Ken Lamb, Brownstone Resources Inc.

Phase One is proposed to include a limited drill program to further test the zone at depth, along with core sampling and assaying, followed by additional prospecting, claim staking, and more surface sampling.

Brownstone will announce a start date for commencement of work once the plan has been approved.

ACCENTIA BIOPHARMACEUTICALS INCORPORATED (NASDAQ: ABPI)
"Up 12.93% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ABPI.php

Immunosyn Corporation, a development stage company, engages in the marketing, distribution, and sale of a biopharmaceutical drug product, SF-1019. The company owns license rights from Argyll Biotechnologies, LLC to offer SF-1019, an experimental extract from caprine serum containing various lipopeptide molecules. SF-1019 is used for the treatment of various diseases and pathological conditions, including Chronic Inflammatory Demyelinating Polyneuropathy, Diabetic Neuropathy, and diabetic ulcers. The company was founded in 2006 and is headquartered in La Jolla, California. Immunosyn Corporation is a subsidiary of Argyll Biotechnologies, LLC.

ABPI News:

July 17 - Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID® Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial

* Overall median disease-free-survival increased by more than one year (p-value = 0.047)
* 100% improvement in disease-free-survival at three years (p-value = 0.024)
* Potential to be first ever anti-cancer vaccine approved in U.S. and/or Europe

Biovest International, Inc. (OTCBB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI), announced clinically and statistically significant unblinded data from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial of BiovaxID® (personalized anti-idiotype vaccine) for the treatment of indolent follicular non-Hodgkin’s lymphoma (NHL), an often fatal blood cancer. Originally developed and advanced into human clinical trials by the National Cancer Institute (NCI), BiovaxID is designed to recruit the immune system to recognize and destroy only cancerous B-cells. Based on this study’s highly encouraging clinical evidence reporting on vaccinated patients to date, including efficacy and safety, Biovest intends to move forward with plans to seek accelerated and/or conditional regulatory approvals in the U.S. and European Union, respectively.

Summary Results

Biovest reported on two clinically relevant data points: 1) Overall median disease-free survival data as measured up to 80 months; and 2) Disease-free survival data on these same patients as measured at three years. All analyses performed were predetermined prior to unblinding and consistent with the Statistical Analysis Plan that was submitted and accepted by the FDA and the data review performed by the independent Data Monitoring Committee (DMC), which is vested with the responsibility for monitoring the safety and efficacy of the BiovaxID trial.

First, for vaccinated patients followed up to 80 months, the overall results showed that BiovaxID improved median disease-free-survival by more than one year with the control arm showing a median time to relapse from first vaccination of 21.2 months, as compared to the BiovaxID arm which had a median time to relapse of 33.8 months. This statistically significant difference (p-value = 0.047) represents an increase of approximately 60% in the duration of complete remission since first vaccination. Disease-free survival (how long patients remain in cancer-free remission) is the primary endpoint of the study.

Second, for these same patients measured at 36 months from vaccination, BiovaxID improved median disease-free-survival by approximately 100% — a statistically significant improvement as compared to the control group (p-value = 0.024).

Biovest intends to seek accelerated and/or conditional approvals immediately in the U.S. and Europe, respectively, based on the current unblinded data and plans to supplement the clinical analysis with additional follow-up data through August 29, 2008, as per the recommendation of the DMC.

According to the Leukemia & Lymphoma Society, non-Hodgkin’s lymphoma is the 5th leading cause of new cancer cases in the U.S., with an estimated 63,190 new cases of NHL to be diagnosed in 2008, with approximately 18,660 deaths expected to be attributed to the disease. In Europe, NHL is the 6th most common form of cancer with approximately 50,000 new cases diagnosed each year in the European Union alone.

ABOUT BIOVAXID®

BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, we anticipate that BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.

ABOUT BIOVEST INTERNATIONAL, INC.

Biovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ: ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently completing a pivotal Phase 3 clinical trial for BiovaxID®, which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.

RIT TECHNOLOGIES LIMITED (NASDAQ: RITT)
"Up 19.05% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/RITT.php

RiT Technologies, Ltd. develops intelligent physical layer management solutions. Its products include PatchView, an intelligent infrastructure management solution that provides real-time connectivity information to the data network's connectivity infrastructure; SMART Cabling System, a structured cabling system for commercial buildings; and PairView, an outside plant management and qualification system, which enables telephone companies to identify, record, and test the connectivity routing of local loop pairs and updating the telephone companies' database. The company also offers PairQ, a digital subscriber line (DSL) mass loop qualification product line that qualifies existing copper infrastructure for the provision of DSL services; and PairView Pro, a local loop mass verification system, which identifies and maps various digital services carried on a line. RiT Technologies markets its solutions primarily through distributors, strategic alliance partners, value-added resellers, system integrators, original equipment manufacturers, and installers. The company serves customers in the United States, Europe, Israel, Latin America, the Asia Pacific, and Africa. It has strategic partnerships with Panduit Corporation, LS Cables, Connectix, Brand-Rex, Belden/CDT, and ADC for the sale of its PatchView system. The company was founded in 1989 and is headquartered in Tel Aviv, Israel.

RITT News:

July 17 - RiT Receives Orders Totaling Several Million Dollars From Two Major Carriers

Kazakhstan's National Carrier Chooses RiT/3M as Part of Nationwide Project to Modernize and Digitalize its Local Loop

RiT Delivers Repeat Order to Leading East European Telco

RiT Technologies (NASDAQ: RITT), the world-leading provider of intelligent infrastructure solutions, today announced that it has received orders totaling several million dollars from its distributor 3M (NYSE: MMM) on behalf of JSC Kazakhtelecom, Kazakhstan's national carrier, and an Eastern European national telecommunications service provider.

The Kazakhtelecom order was made after the successful completion of an extensive competitive tender process, during which the Company and 3M jointly proposed an advanced nationwide telecommunications infrastructure solution. Kazakhtelecom will be deploying RiT's state-of-the-art PairView#(TM) (PairView Sharp) local loop verification and operations support solution in conjunction with its PairQ(TM) xDSL mass-qualification solution.

As part of the deployment process, the Company will be localizing its Carrier software and documentation to the Russian language, an effort that will enhance RiT's ability to market in the Commonwealth of Independent States (CIS).

Commenting on the news Mr. A. Popov, Technical director of Almatytelecom, the largest branch of JSC Kazakhtelecom, said, "RiT manufactures unique, first class products which will allow us to considerably reduce the quantity of personnel required to carry out our ongoing inventory accounting and management initiatives. The equipment will allow us to automate the preparation and execution of many processes, enabling us to accelerate the completion of our large-scale, national infrastructure and network modernization projects."

The other leading East European telecommunications service provider has been using RiT's PairView Pro systems for the past two years, and is now adding PairView# as part of its strategy for rolling out Next Generation 'Triple Play' services.

Initial deliveries of the equipment were completed during the second quarter, while the majority of the equipment is scheduled to be delivered during the third quarter.

Mr. F. Huber, MD of 3M East AG, commented, "Our cooperation with RiT has enabled us to offer an extremely compelling solution to both Kazakhtelecom and another leading carrier, both of which are leading players in the telecommunications revolution currently underway throughout the CIS. By combining RiT's advanced mapping and monitoring solutions with our product platform, we are able to bring a new level of visibility to the last-mile network, giving operators the tools they need to achieve efficiency in physical plant planning and deployment."

"We are very pleased to report these important sales, both of which demonstrate the success of our sales and support organizations in the CIS and Eastern Europe," added Mr. Avi Kovarsky, RiT's President & CEO. "Our success reflects the strength of our cooperation with 3M, which has enabled us to propose a uniquely comprehensive, field-proven solution. Looking forward, given our expanded regional references and newly localized products, we feel particularly well positioned to continue building our business throughout these dynamic regions."

ABOUT 3M COMPANY

A recognized leader in research and development, 3M produces thousands of innovative products for dozens of diverse markets. 3M's core strength is applying its more than 40 distinct technology platforms - often in combination - to a wide array of customer needs. With $24 billion in sales, 3M employs 75,000 people worldwide and has operations in more than 60 countries. For more information, visit www.3M.com.

ABOUT JSC KAZAKHTELECOM

JSC Kazakhtelecom is the national telecommunication operator of Kazakhstan and one of the fastest developing telecommunication companies in the Former Soviet Union region. The company currently serves approximately three million subscribers, and is engaged in an extensive project to expand network coverage while modernizing and digitalizing its infrastructure. As a result of its accomplishments, the company was named "Best Telecommunications Company in Central Asia" by Euromoney Magazine in 2006.